Stephen Chmura
Stanford University
4 Papers
Stephen Chmura is an academic researcher from Stanford University. The author has contributed to research in topics: Influenza A virus & Coronavirus. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Timothy R. Abbott,Girija Dhamdhere,Yanxia Liu,Xueqiu Lin,Laine E. Goudy,Leiping Zeng,Augustine Chemparathy,Stephen Chmura,Nicholas S. Heaton,Robert J. Debs,Tara Pande,Drew Endy,Marie La Russa,David B. Lewis,Lei S. Qi +14 more
TL;DR: A CRISPR-Cas13-based strategy for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus in human lung epithelial cells is demonstrated and has the potential to become an important pan-coronavirus inhibition strategy.
436
Durable multitransgene expression in vivo using systemic, nonviral DNA delivery
Chakkrapong Handumrongkul,Alice L. Ye,Stephen Chmura,Liliana Soroceanu,Marissa Mack,Ryan J Ice,Robert Thistle,Methawee Myers,Sarah Ursu,Yong Liu,Mohammed Kashani-Sabet,Timothy D. Heath,Denny Liggitt,David B. Lewis,Robert J. Debs +14 more
TL;DR: HEDGES can produce extended therapeutic levels of multiple transgene-encoded therapeutic human proteins from DNA inserts >1.5-fold larger than AAV-based therapeutics, thus creating combinatorial interventions to effectively treat common polygenic diseases driven by multigenic abnormalities.
17
The ratio of circulating regulatory cluster of differentiation 4 T cells to endothelial progenitor cells predicts clinically significant acute rejection after heart transplantation.
Dong-Hyun Choi,Stephen Chmura,Vasavi Ramachandran,Kira Y. Dionis-Petersen,Yuhei Kobayashi,Takeshi Nishi,Helen Luikart,Sadia Dimbil,Jon A. Kobashigawa,Kiran K. Khush,David B. Lewis,William F. Fearon +11 more
TL;DR: The Treg/EPC ratio measured soon after heart transplantation is an independent predictor of acute rejection and has potential as an early biomarker after heart transplants for predicting acute rejection.
6
Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
Timothy R. Abbott,Girija Dhamdhere,Yanxia Liu,Xueqiu Lin,Laine E. Goudy,Leiping Zeng,Augustine Chemparathy,Stephen Chmura,Nicholas S. Heaton,Robert J. Debs,Tara Pande,Drew Endy,Marie La Russa,David B. Lewis,Lei S. Qi +14 more
TL;DR: A CRISPR-Cas13-based strategy, PAC-MAN (Prophylactic AntiviralCRISPR in huMAN cells), for viral inhibition that can effectively degrade SARS-CoV-2 sequences and live influenza A virus genome in human lung epithelial cells is demonstrated.